Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Medicis to Acquire LipoSonix and NPS Pharmaceuticals Notified of ANDA Filings for Cinacalcet HCl
Jun 17, 2008 08:59 AM
- Neurobiological Technologies Sets Date for Third Quarter Financial Results and GATTEX(TM) Abstracts Accepted for Presentation at DDW Conference; Phase 3 Short Bowel Syndrome Results Scheduled for Oral Plenary Session and GATTEX(TM) Abstracts Accepted for Presentation at DDW Conference; Phase 3 Short Bowel Syndrome Results Scheduled for Oral Plenary Session
May 08, 2008 11:29 AM
- NASDAQ Technical Picture - Bearish Outside Day
May 08, 2008 01:10 AM
- CytRx Corporation (Public, NASDAQ:CYTR)
Oct 15, 2007 02:34 AM
- Amylin Pharmaceuticals to Webcast Third Quarter Results and Gilead Submits Marketing Applications in the United States and European Union for Viread(R) (Tenofovir Disoproxil Fumarate) for the Treatment of Chronic Hepatitis B
Oct 12, 2007 09:28 AM
- Genzyme Spent $1.3M Lobbying and NPS Pharmaceuticals Names Brian O'Callaghan as New Chief Commercial Officer
Oct 09, 2007 09:29 AM
- ViroPharma to Present at the Natixis Bleichroeder Conference and NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for October 17, 2007
Oct 04, 2007 09:29 AM
- NASDAQ Technical Picture - Profit Taking on Higher Volume
Oct 04, 2007 07:08 AM
- NASDAQ Technical Picture - QQQQ Tests July Highs Post Fed
Sep 20, 2007 09:22 AM
- Pre-Market - Wednesday September 12th
Sep 12, 2007 12:19 PM
- NPS Pharmaceuticals Appoints Roger Garceau as Chief Medical Officer
Dec 03, 2008 08:07 AM
- NPS Pharmaceuticals Initiates Phase 3 ‘STEPS’ Study to Confirm GATTEX™ Reduces Parenteral Nutrition Dependence in Short Bowel Syndrome
Dec 02, 2008 08:18 AM
- NPS Pharmaceuticals to Present at Piper Jaffray Health Care Conference
Nov 21, 2008 03:46 PM
- NPS Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference
Nov 06, 2008 04:53 PM
- NPS Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
Nov 05, 2008 07:46 AM
- NPS Pharmaceuticals to Report Third Quarter 2008 Financial Results
Oct 31, 2008 05:02 PM
- NPS Pharmaceuticals Announces Multiple GATTEX(TM) Data Presentations at 16th United European Gastroenterology Week Meeting
Oct 15, 2008 04:13 PM
- One Year of GATTEX(TM) Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome
Oct 08, 2008 09:51 AM
- GATTEX(TM) Abstracts to be Presented at ACG Meeting; 52-Week Data from Phase 3 Clinical Trial Scheduled for Plenary Session
Sep 23, 2008 04:11 PM
- Positive Interim Data from Phase 2 Study of NPSP558 (Parathyroid Hormone 1-84) for Hypoparathyroidism Reported at ASBMR Annual Meeting
Sep 15, 2008 08:12 AM
- Form 4 Rackear Andrew D. For: Oct 15 (10K)
Oct 20, 2008 11:57 AM
- Form 4 NPS PHARMACEUTICALS INC For: Oct 15 Filed by: BESHAR LUKE M (10K)
Oct 20, 2008 11:50 AM
- Form 4 NPS PHARMACEUTICALS INC For: Oct 15 Filed by: BONNEY MICHAEL W (10K)
Oct 17, 2008 05:27 PM
- Form 4 NPS PHARMACEUTICALS INC For: Oct 15 Filed by: GRONINGER JAMES G (10K)
Oct 17, 2008 05:27 PM
- Form 4 NPS PHARMACEUTICALS INC For: Oct 15 Filed by: KUHLA DONALD E (10K)
Oct 17, 2008 05:27 PM
- Form 4 NPS PHARMACEUTICALS INC For: Oct 15 Filed by: Selisker Rachel R (10K)
Oct 17, 2008 05:27 PM
- Form 4 NPS PHARMACEUTICALS INC For: Oct 15 Filed by: DOBAK DOUGLAS N (10K)
Oct 17, 2008 05:25 PM
- Form 4 NPS PHARMACEUTICALS INC For: Oct 15 Filed by: Nader Francois (10K)
Oct 17, 2008 05:25 PM
- Form 4 NPS PHARMACEUTICALS INC For: Oct 15 Filed by: TOMBROS PETER G (10K)
Oct 17, 2008 05:24 PM
- Form 4 NPS PHARMACEUTICALS INC For: Sep 19 Filed by: BVF INC/IL (10K)
Sep 23, 2008 06:27 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
NPSP
|
Compare to S&P
|
| YTD |
62.66 %
|
-0.01 %
|
| 4 Weeks |
-15.58 %
|
0.03 %
|
| 12 Weeks |
-26.18 %
|
6.49 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -133.33 %
|
|
EPS Growth in Last Year: -105.56 %
|
|
Sales Growth in Last Quarter: -3.28 %
|
|
Sales Growth in Last Quarter: -10.58 %
|
|
|
